Ospemifene: A Novel Oral Therapy for Vulvovaginal Atrophy of Menopause.
J Obstet Gynaecol Can
; 42(3): 301-303, 2020 Mar.
Article
in English
| MEDLINE | ID: covidwho-1291550
ABSTRACT
Vulvovaginal atrophy (VVA) resulting from estrogen deprivation at menopause often results in distressing vaginal dryness and dyspareunia. Fewer than 25% of affected women seek help for this condition citing embarrassment, cultural values, an aging or unavailable partner and concerns about use of estrogens following the Women's Health Initiative. Available non-hormonal treatments, such as moisturizers, while affording some relief can be messy to apply and do not prevent disease progression. A new oral selective estrogen receptor modulator, ospemifene, has been found to have strong estrogenic activity in vaginal tissues without adverse estrogenic effects at other sites.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Atrophy
/
Tamoxifen
/
Vagina
/
Vulva
/
Menopause
/
Selective Estrogen Receptor Modulators
Limits:
Aged
/
Female
/
Humans
/
Middle aged
Language:
English
Journal:
J Obstet Gynaecol Can
Journal subject:
Gynecology
/
Obstetrics
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS